Publication
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
Ackerman SE, et al., Nature Cancer (2020)
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
Ackerman SE, et al., Nature Cancer (2020)
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 San Antonio Breast Cancer Symposium
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner
Presented at: 2019 Society for Immunotherapy of Cancer (SITC)
TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity
Presented at: 2019 American Association for Cancer Research (AACR)
Systemic Immunity is Required for Effective Cancer Immunotherapy
Spitzer MH, et al. Cell (2017)
Allogenic IgG Combined with Dendritic Cell Stimuli Induce Antitumor T-cell Immunity
Carmi Y, et al. Nature (2015)